BVNRY:OTCMKTS
Bavarian Nordic
11,78 US$
arrow_downward
−1,54%(−0,18) 1 d
13 okt., 11:42:04 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för BVNRY …
Öppen
11,77 US$
Högt
11,78 US$
Lågt
11,77 US$
Börsvärde
2,81 md
Genomsn. vol.
3,04 tn
Volym
742,00
P/E-tal
12,70
52v högst
13,00 US$
52v lägst
8,67 US$
EPS
0,93 US$
Beta
1,45
Utestående aktier
237,82 mn
Antal anställda
2 tn
Öppen
11,77 US$
Högt
11,78 US$
Lågt
11,77 US$
Börsvärde
2,81 md
Genomsn. vol.
3,04 tn
Volym
742,00
P/E-tal
12,70
52v högst
13,00 US$
52v lägst
8,67 US$
EPS
0,93 US$
Beta
1,45
Utestående aktier
237,82 mn
Antal anställda
2 tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
GlobeNewswire
·
för 1 dag sedan
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Profil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Om Bavarian Nordic